SENECA Trial Supports Potential Safety, Feasibility of allo-MSC in AIC Patients
Transendocardial injection of allogeneic mesenchymal stromal cells (allo-MSCs) may be safe and feasible in patients with anthracycline-induced cardiomyopathy (AIC), according to findings from the SENECA trial presented Sept. 30 during the Heart Failure Society of America Virtual Annual Scientific Meeting 2020 and simultaneously published in JACC: CardioOncology.
Importantly, the trial also demonstrates that cardiac CMR may be effectively used in heart failure patients despite the high prevalence of devices.
"This phase 1 study met its primary objectives by demonstrating that allo-MSCs are well-tolerated, that they could be delivered as planned and that the outcome measures could be collected successfully," the authors conclude.
"Our exploratory evaluation of efficacy endpoints will be important to design phase 2 and 3 studies. Taken together, these results provide the necessary groundwork for future larger studies focused on efficacy of cell therapy in AIC patients." Read more.